Study Design: Unblinded, single centre, repeatability study
Disease Area: Oncology (Renal Cell Carcinoma, and Melanoma)
Funder: ImaginAb
Sponsor: ImaginAb
Chief Investigator: Dr Azeem Saleem
Trial Registration: ISRCTN71215418

Positron Emission Tomography Repeatability Evaluation of Tissue Zirconium 89Zr Crefmirlimab Berdoxam Uptake (PRETZCEL)


Positron emission tomography (PET) scans are used to produce images of the inside the body and can be used to investigate cancer and help decisions on how best to treat patients. PET scans are often combined with CT scans to produce even more detailed images, this is known as a PET-CT scan. In this study, we want to test if a new imaging agent, called 89Zr  crefmirlimab berdoxam, could be used in PET-CT scanning.

We first want to understand if it behaves in the same manner when it is given twice under similar conditions. The new imaging agent is a modified form of an antibody (or a minibody) to which a small amount of radioactivity is attached. After intravenous injection into the body, this modified radioactive minibody attaches itself to a type of immune cell called a CD-8+ T-cell. The imaging agent allows us to track the behaviour of the CD8+ T cells that play an important role in killing cancer cells. Some cancer patients have CD8+ cells around their tumours and these have been shown to attack and kill cancer cells. Giving the new imaging agent before a PET-CT scan could help doctors see where CD8+ T cells are located. This information may tell doctors how well a patient will respond to immunotherapy treatments.

If we find that the imaging agent behaves in a similar way when given twice under similar conditions, it may help in the development of new drugs that target the immune system and allow doctors to tailor the treatment of patients with cancer.

What we plan to do

This study will include a total of 12 participants all recruited from the Hull University Teaching Hospitals NHS Trust. 6 participants will have a diagnosis of renal cell carcinoma and 6 will have malignant melanoma. The study will be open to recruitment for approximately 12 months.

Chief Investigator

Dr Azeem Saleem Reader and Honorary Consultant in Oncology - Hull York Medical School, and Hull University Hospitals NHS Trust

HHTU Study team

Bronwen Williams - Operations Manager
Martina Santarelli - Trial Manager
Sarah Sumpter - Senior Data Manager
Phillip Best - Data Manager
Dr Chao Huang - Statistician


Michael Ferris Associate Director, Operations - ImaginAb
Gareth Smith VP Business Strategy - ImaginAb

Email Address

Participating sites and their Project Investigators 

  • Castle Hill Hospital, Hull Teaching Hospitals NHS Trust - Dr Azeem Saleem

Read the Privacy Notice here.



Watch this space